NEWRON PHARMA N (NWRN.SW)


Swiss - Swiss Delayed Price. Currency in CHF
23.40+0.10 (+0.43%)
At close: 11:30 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open23.50
Prev Close23.30
Bid22.80 x 113400
Ask23.35 x 50200
Day's Range22.70 - 23.50
52wk Range13.85 - 30.90
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume19,400
Avg Vol (3m)30,503
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Business Wirelast month

    Newron to Re-Submit US NDA for Xadago® (Safinamide)

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, and its partners Zambon S.p.A.

  • Business Wirelast month

    Newron Pharmaceuticals Announces Initiation of the STARS Study in the United States

    Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, today announced the initiation of the Sarizotan Treatment of Apneas in Rett Syndrome study, a potentially pivotal clinical study to evaluate the efficacy, safety and tolerability of sarizotan in patients with Rett syndrome suffering ...

  • Business Wire2 months ago

    Zambon Launches Xadago® (Safinamide) in the Netherlands for Patients with Mid- to Late-Stage Parkinson’s Disease

    Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system therapeutic area, and its partner Newron Pharmaceuticals S.p.A. , a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system and pain, today announced the launch of Xadago® in the Netherlands for the treatment of mid- to late-stage ...